Tools

lanternpharma.com), an investigational drug candidate to treat glioblastoma. HC-7366 (HiberCell Inc., a GCN2-targeting agent, received fast track designation from the FDA for the treatment of adult patients with relapsed or refractory acute myeloid leukemia. The FDA granted orphan drug designation for MB-108 (Mustang, mustangbio.com), a herpes simplex virus type 1 oncolytic virus, for the treatment of malignant glioma.

Publication Details

Journal
Oncology Issues
Published
2024-12-01
DOI
https://doi.org/10.3928/25731777-20241213-16
Primary Topic
Virus-based gene therapy research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Tools

Oncology Issues
Virus-based gene therapy research
article

Tools

article en

Abstract

lanternpharma.com), an investigational drug candidate to treat glioblastoma. HC-7366 (HiberCell Inc., a GCN2-targeting agent, received fast track designation from the FDA for the treatment of adult patients with relapsed or refractory acute myeloid leukemia. The FDA granted orphan drug designation for MB-108 (Mustang, mustangbio.com), a herpes simplex virus type 1 oncolytic virus, for the treatment of malignant glioma.

Oncology IssuesVol. 39(6)
Openalex Percentile: Top 74%
Virus-based gene therapy research
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Tools · Oncology Issues (2024) | TGRS Research Map | TGRS